Welchen Stellenwert haben Ribonucleinsäuren in der Tumortherapie?

Abstract: There are a lot of publications about the influence of RNA on tumours and on the complications of tumour therapy. Various clinical trials for testing the direct anti-tumour-effect of RNA of different origin and structure were carried out e.g. with patients suffering from metastasizing kidney cancer, advanced melanome, and coIon cancer. 2-4 mg of RNA per diem (exceptionally up to 60 mg per week) were used for times up to 40 month.In the second part single cases of the direct treatment of tumourpatients with Regeneresen are documented. In most cases 36 mg of RNA were used per week for more than 5 months resp. total doses of 600 mg up to > 2000 mg. The results respecting the success of the therapies can be compared with those from the international literature cited above.

Keyword(s): Ribonucleinsäuren (RNA)

Zurück | Weiter